Trials / Completed
CompletedNCT01933945
Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib
OPTIMIS - Outcomes of HCC Patients Treated With TACE Followed or Not Followed by Sorafenib and the Influence of Timing to Initiate Sorafenib
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,676 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study will collect data of patients who are treated with TACE followed by sorafenib for hepatocellular carcinoma (HCC) or patients without Sorafenib after TACE. In contrast to a prior observational study on sorafenib (GIDEON study), where pre-treatment with TACE was documented retrospectively, this study will collect more detailed information about the TACE treatment and the status of a patient when treatment with sorafenib is started.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | TACE (transarterial chemoembolization) | First treatment for all patients included in the study |
| DRUG | Sorafenib (Nexavar, BAY43-9006) |
Timeline
- Start date
- 2013-10-28
- Primary completion
- 2017-07-22
- Completion
- 2017-11-10
- First posted
- 2013-09-02
- Last updated
- 2018-11-06
Locations
31 sites across 31 countries: Austria, Brazil, Canada, China, Czechia, Denmark, Egypt, France, Greece, Hong Kong, Hungary, India, Indonesia, Israel, Japan, Kazakhstan, Mexico, Netherlands, Pakistan, Poland, Russia, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), Vietnam
Source: ClinicalTrials.gov record NCT01933945. Inclusion in this directory is not an endorsement.